// App-Quantinova.ai

DOP50 : Effect of upadacitinib on extra-intestinal manifestations in patients with moderate to severe Crohn’s disease: data from the CELEST study

Researchers

Presenter

  • L Peyrin-Biroulet

Principal Investigators

  • S Danese

  • E Louis

  • P D R Higgins

  • M Dubinsky

  • F Cataldi

  • Q Zhou

  • W-J Lee

  • K Kligys

  • A P Lacerda

Medical Centers

  • University of Lorraine, Nancy, France

  • Istituto Clinico Humanitas, Milan, Italy

  • CHU de Liège et Université de Liège, Liège, Belgium

  • University of Michigan, Ann Arbor, MI

  • Icahn School of Medicine at Mount Sinai, New York, NY

  • AbbVie, Inc., North Chicago, IL

Locations

  • France

  • Italy

  • Belgium

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

  • Ophthalmology (OP)

  • Gastroenterology (GU)

  • Genetic Disorder

  • Infectious Diseases (ID)

  • Dermatology

  • Autoimmune (AI)

  • Cardiovascular (CVS)

  • Nephrology

  • Musculoskeletal

  • Blood/haematological Diseases

Disease

  • Chronic obstructive pulmonary disease

  • Primary sclerosing cholangitis

  • Venous thrombosis

  • Erythema nodosum leprosum

  • Sweet's syndrome

  • Crohn's disease

  • Nephrolithiasis, calcium oxalate

  • Ascending cholangitis

  • Uveitis

Biomarkers

  • Plasminogen Activator, Urokinase

Drug/Treatment

  • ABT-494

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Multicenteric

  • Controlled

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved